PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk
Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers...
Saved in:
| Published in | International journal of molecular sciences Vol. 24; no. 3; p. 2319 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
24.01.2023
MDPI |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1422-0067 1661-6596 1422-0067 |
| DOI | 10.3390/ijms24032319 |
Cover
| Abstract | Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001). It also increased apoA-I (2.05%, p = 0.043) and HDL cholesterol levels (11.58%, p < 0.001). Circulating PCSK9 levels increased six-fold (626.28%, p < 0.001). The decrease in Glyc signals positively correlated with the decrease in triglycerides and apoC-III. In conclusion, in addition to LDL cholesterol, iPCSK9 therapy also induces a reduction in systemic inflammation measured by 1H-NMR glycoprotein signals, which correlates with a decrease in triglycerides and apoC-III. |
|---|---|
| AbstractList | HighlightsWhat are the main findings?PCSK9 inhibition significantly reduces 1H-NMR glycoprotein signals and does not affect hsCRP levels.Apolipoprotein C-III and triglycerides are also decreased by iPCSK9.The decrease in glycoproteins correlates with the decrease in apoC-III and TG.What is the implication of the main finding?PCSK9 inhibition significantly reduces inflammationAbstractAtherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001). It also increased apoA-I (2.05%, p = 0.043) and HDL cholesterol levels (11.58%, p < 0.001). Circulating PCSK9 levels increased six-fold (626.28%, p < 0.001). The decrease in Glyc signals positively correlated with the decrease in triglycerides and apoC-III. In conclusion, in addition to LDL cholesterol, iPCSK9 therapy also induces a reduction in systemic inflammation measured by 1H-NMR glycoprotein signals, which correlates with a decrease in triglycerides and apoC-III. Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, < 0.001), LDL (55.05%, < 0.001) and non-high-density lipoprotein (HDL) (45.11%, < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, < 0.001), triglycerides (9.92%, < 0.001) and glycoprotein signals GlycA (11.97%, < 0.001), GlycB (3.83%, = 0.017) and GlycF (7.26%, < 0.001). It also increased apoA-I (2.05%, = 0.043) and HDL cholesterol levels (11.58%, < 0.001). Circulating PCSK9 levels increased six-fold (626.28%, < 0.001). The decrease in Glyc signals positively correlated with the decrease in triglycerides and apoC-III. In conclusion, in addition to LDL cholesterol, iPCSK9 therapy also induces a reduction in systemic inflammation measured by 1H-NMR glycoprotein signals, which correlates with a decrease in triglycerides and apoC-III. Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001). It also increased apoA-I (2.05%, p = 0.043) and HDL cholesterol levels (11.58%, p < 0.001). Circulating PCSK9 levels increased six-fold (626.28%, p < 0.001). The decrease in Glyc signals positively correlated with the decrease in triglycerides and apoC-III. In conclusion, in addition to LDL cholesterol, iPCSK9 therapy also induces a reduction in systemic inflammation measured by 1H-NMR glycoprotein signals, which correlates with a decrease in triglycerides and apoC-III.Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001). It also increased apoA-I (2.05%, p = 0.043) and HDL cholesterol levels (11.58%, p < 0.001). Circulating PCSK9 levels increased six-fold (626.28%, p < 0.001). The decrease in Glyc signals positively correlated with the decrease in triglycerides and apoC-III. In conclusion, in addition to LDL cholesterol, iPCSK9 therapy also induces a reduction in systemic inflammation measured by 1H-NMR glycoprotein signals, which correlates with a decrease in triglycerides and apoC-III. Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001). It also increased apoA-I (2.05%, p = 0.043) and HDL cholesterol levels (11.58%, p < 0.001). Circulating PCSK9 levels increased six-fold (626.28%, p < 0.001). The decrease in Glyc signals positively correlated with the decrease in triglycerides and apoC-III. In conclusion, in addition to LDL cholesterol, iPCSK9 therapy also induces a reduction in systemic inflammation measured by 1H-NMR glycoprotein signals, which correlates with a decrease in triglycerides and apoC-III. |
| Author | Díaz-Díaz, José Luis Masana, Lluís Recasens, Lluís Plana, Núria Amigó, Núria Girona, Josefa Esteban, Yaiza Guardiola, Montse Muñiz-Grijalvo, Ovidio Rehues, Pere Rosales, Roser Ribalta, Josep Ibarretxe, Daiana Pinyol, Marta Piro, Salvatore Scicali, Roberto |
| AuthorAffiliation | 5 Department of Clinical and Experimental Medicine, University of Catania, 95131 Catania, Italy 7 Department of Internal Medicine, Complejo Hospitalario Universitario A Coruña, 15006 A Coruña, Spain 3 Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, 28029 Madrid, Spain 1 Universitat Rovira i Virgili, Departament de Medicina i Cirurgia, Unitat de Recerca en Lípids i Arteriosclerosi, 43201 Reus, Spain 6 Unidad Clinico-Experimental de Riesgo Vascular, Hospital Virgen del Rocío, 41013 Sevilla, Spain 2 Institut d’Investigació Sanitària Pere Virgili, 43204 Reus, Spain 9 Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, 08003 Barcelona, Spain 4 Unitat de Medicina Vascular i Metabolisme, Servei de Medicina Interna, Hospital Universitari Sant Joan de Reus, 43204 Reus, Spain 10 Biosfer Teslab, 43201 Reus, Spain 8 Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain |
| AuthorAffiliation_xml | – name: 8 Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain – name: 6 Unidad Clinico-Experimental de Riesgo Vascular, Hospital Virgen del Rocío, 41013 Sevilla, Spain – name: 7 Department of Internal Medicine, Complejo Hospitalario Universitario A Coruña, 15006 A Coruña, Spain – name: 2 Institut d’Investigació Sanitària Pere Virgili, 43204 Reus, Spain – name: 5 Department of Clinical and Experimental Medicine, University of Catania, 95131 Catania, Italy – name: 10 Biosfer Teslab, 43201 Reus, Spain – name: 1 Universitat Rovira i Virgili, Departament de Medicina i Cirurgia, Unitat de Recerca en Lípids i Arteriosclerosi, 43201 Reus, Spain – name: 3 Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, 28029 Madrid, Spain – name: 4 Unitat de Medicina Vascular i Metabolisme, Servei de Medicina Interna, Hospital Universitari Sant Joan de Reus, 43204 Reus, Spain – name: 9 Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, 08003 Barcelona, Spain |
| Author_xml | – sequence: 1 givenname: Pere surname: Rehues fullname: Rehues, Pere – sequence: 2 givenname: Josefa orcidid: 0000-0002-6267-8779 surname: Girona fullname: Girona, Josefa – sequence: 3 givenname: Montse orcidid: 0000-0002-9696-7384 surname: Guardiola fullname: Guardiola, Montse – sequence: 4 givenname: Núria surname: Plana fullname: Plana, Núria – sequence: 5 givenname: Roberto orcidid: 0000-0002-7023-3649 surname: Scicali fullname: Scicali, Roberto – sequence: 6 givenname: Salvatore orcidid: 0000-0002-1781-0902 surname: Piro fullname: Piro, Salvatore – sequence: 7 givenname: Ovidio surname: Muñiz-Grijalvo fullname: Muñiz-Grijalvo, Ovidio – sequence: 8 givenname: José Luis orcidid: 0000-0002-9194-495X surname: Díaz-Díaz fullname: Díaz-Díaz, José Luis – sequence: 9 givenname: Lluís surname: Recasens fullname: Recasens, Lluís – sequence: 10 givenname: Marta surname: Pinyol fullname: Pinyol, Marta – sequence: 11 givenname: Roser surname: Rosales fullname: Rosales, Roser – sequence: 12 givenname: Yaiza surname: Esteban fullname: Esteban, Yaiza – sequence: 13 givenname: Núria orcidid: 0000-0002-0116-9145 surname: Amigó fullname: Amigó, Núria – sequence: 14 givenname: Lluís orcidid: 0000-0002-0789-4954 surname: Masana fullname: Masana, Lluís – sequence: 15 givenname: Daiana surname: Ibarretxe fullname: Ibarretxe, Daiana – sequence: 16 givenname: Josep orcidid: 0000-0002-8879-4719 surname: Ribalta fullname: Ribalta, Josep |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36768645$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkkuLFDEURgsZcR66cy0BNy6mNI96ZSM0jU4Xjjr06DokqVvTaVOVniTV0L_JP2naedAOQiA35NzDF3JPs6PRjZBlrwl-zxjHH8x6CLTAjDLCn2UnpKA0x7iqjw7q4-w0hDXGlNGSv8iOWVVXTVWUJ9nvq_n1F47acWWUic4HtJBbQLONs2bjNt5FMCOa523b5kuwMkKHZmM0eTv2Vg6DTD07NNPRbE3cnaNZCJBWh9QOkUX-7esSXdidfjRdedcbCyiV15Nag44ByYgW5maFnEdbSLa_h7n0nXFbGfRkpUdLE369zJ730gZ4db-fZT8_f_oxX-SX3y_a-ewy1wWhMQfZFJ0EVeqC8x7rvioUUaoppGqgrAmVhJeUEwYFwarsOlANKxsKRMkGK8bOso933s2kBug0jNFLKzbeDNLvhJNG_HszmpW4cVvBOUl6nATv7gXe3U4QohhM0GCtHMFNQdC6Lita1qxJ6Nsn6NpNfkzP21MFJ6SkdaLeHCZ6jPLwjwmgd4D2LgQPvdAmymjcPqCxgmCxHxZxOCyp6fxJ04P3v_gf5vXCqQ |
| CitedBy_id | crossref_primary_10_1016_j_jacbts_2024_06_008 crossref_primary_10_3390_ijms241310659 crossref_primary_10_1016_j_jdiacomp_2023_108593 crossref_primary_10_1186_s12950_023_00358_7 crossref_primary_10_1038_s41392_023_01690_3 crossref_primary_10_1007_s10557_024_07587_9 crossref_primary_10_1186_s12933_024_02553_z crossref_primary_10_1021_acs_jproteome_2c00847 crossref_primary_10_1186_s12933_024_02531_5 crossref_primary_10_3390_ijms25031752 |
| Cites_doi | 10.1161/JAHA.121.023328 10.1161/CIRCRESAHA.118.311227 10.1161/CIRCULATIONAHA.118.034645 10.21037/jlpm.2020.03.03 10.3892/ijmm.2012.1072 10.1038/s41598-018-20425-x 10.1016/S0735-1097(14)61389-9 10.1373/clinchem.2014.232918 10.1016/j.ajpc.2022.100373 10.1038/ni.2001 10.1161/CIRCRESAHA.116.308537 10.1016/j.jpba.2009.01.008 10.2337/dc16-1569 10.1038/nrneph.2017.51 10.1021/acs.jproteome.8b00411 10.1097/MOL.0000000000000372 10.1194/jlr.D050120 10.1016/j.atherosclerosis.2021.06.905 10.1016/j.clim.2018.12.011 10.1016/S0140-6736(14)61399-4 10.1161/JAHA.115.002224 10.1017/S0007114517002100 10.1016/j.jacl.2018.01.002 10.1016/j.jacc.2020.11.079 10.2337/db09-0206 10.1021/acs.jproteome.9b00528 10.1093/cid/civ327 10.1161/CIRCRESAHA.116.309637 10.1016/j.atherosclerosis.2022.09.008 10.21037/atm.2020.01.17 10.1056/NEJMoa1307095 10.1136/bmjopen-2018-022348 10.1056/NEJMoa1501031 10.1161/JAHA.116.003822 10.1016/j.clinbiochem.2014.03.008 10.3390/jcm9020354 10.3390/jcm9082472 10.1056/NEJMoa1707914 10.1161/JAHA.114.001221 10.1186/s12967-017-1321-6 10.1161/CIRCULATIONAHA.105.591743 10.1016/j.jacc.2020.09.610 10.1016/j.jacc.2020.10.008 10.1161/CIRCULATIONAHA.108.814251 10.1007/s00125-017-4426-9 10.1161/CIRCULATIONAHA.118.034942 10.3390/life11121407 10.1001/jama.297.6.611 10.1007/s00392-017-1106-1 10.1007/s11883-014-0435-z 10.1194/jlr.M051326 10.1093/ehjopen/oeac039 10.1111/dom.13273 10.1161/CIRCULATIONAHA.108.813311 10.1172/JCI103182 10.5114/aoms/133885 10.1093/ehjcvp/pvz022 10.1016/S0140-6736(20)32332-1 10.1056/NEJMoa1308027 10.1016/j.amjcard.2017.10.028 10.1093/eurheartj/ehz455 10.1161/CIRCRESAHA.120.315937 |
| ContentType | Journal Article |
| Copyright | 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 by the authors. 2023 |
| Copyright_xml | – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 by the authors. 2023 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.3390/ijms24032319 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1422-0067 |
| ExternalDocumentID | PMC9917120 36768645 10_3390_ijms24032319 |
| Genre | Journal Article Observational Study |
| GrantInformation_xml | – fundername: Ministerio de Universidades, Spain grantid: FPU19/04610 – fundername: Ministry of Economy, Industry and Competitiveness grantid: PI21/01294 – fundername: Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas grantid: CB07/08/0028 – fundername: Sanofi (Spain) grantid: Allied – fundername: SANOFI-Aventis S.A – fundername: CIBERDEM (CIBER de Diabetes y Enfermedades Metabólicas Asociadas) – fundername: Ministerio de Universidades grantid: FPU19/04610 – fundername: Fondo Europeo de Desarrollo Regional (FEDER) – fundername: Spanish Ministerio de Economía y Competitividad grantid: PI21/01294 |
| GroupedDBID | --- 29J 2WC 53G 5GY 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ 8G5 A8Z AADQD AAFWJ AAHBH AAYXX ABDBF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AFKRA AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CITATION CS3 D1I DIK DU5 DWQXO E3Z EBD EBS EJD ESX F5P FRP FYUFA GNUQQ GUQSH GX1 HH5 HMCUK HYE IAO IHR ITC KQ8 LK8 M1P M2O M48 MODMG O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM TR2 TUS UKHRP ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7XB 8FK ESTFP K9. MBDVC PKEHL PQEST PQUKI PRINS PUEGO Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c412t-ea84daeb5c499f0cf64b1bb84ab8e5712a1952913e410b5ddeb83582e1ba80b33 |
| IEDL.DBID | 8FG |
| ISSN | 1422-0067 1661-6596 |
| IngestDate | Thu Aug 21 18:38:39 EDT 2025 Mon Sep 08 04:38:49 EDT 2025 Thu Sep 11 20:25:07 EDT 2025 Mon Jul 21 05:58:45 EDT 2025 Thu Apr 24 23:11:54 EDT 2025 Tue Jul 01 02:03:19 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | PCSK9 alirocumab glycoproteins apolipoprotein C-III LDL inflammation |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c412t-ea84daeb5c499f0cf64b1bb84ab8e5712a1952913e410b5ddeb83582e1ba80b33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0002-8879-4719 0000-0002-0116-9145 0000-0002-7023-3649 0000-0002-9194-495X 0000-0002-9696-7384 0000-0002-0789-4954 0000-0002-6267-8779 0000-0002-1781-0902 |
| OpenAccessLink | https://www.proquest.com/docview/2774911527?pq-origsite=%requestingapplication% |
| PMID | 36768645 |
| PQID | 2774911527 |
| PQPubID | 2032341 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9917120 proquest_miscellaneous_2775625738 proquest_journals_2774911527 pubmed_primary_36768645 crossref_citationtrail_10_3390_ijms24032319 crossref_primary_10_3390_ijms24032319 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20230124 |
| PublicationDateYYYYMMDD | 2023-01-24 |
| PublicationDate_xml | – month: 1 year: 2023 text: 20230124 day: 24 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | International journal of molecular sciences |
| PublicationTitleAlternate | Int J Mol Sci |
| PublicationYear | 2023 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Moncayo (ref_33) 2019; 18 Mokkala (ref_43) 2017; 118 Connelly (ref_45) 2017; 15 Mallol (ref_63) 2015; 56 Tang (ref_16) 2012; 30 Punch (ref_20) 2022; 11 Mach (ref_61) 2020; 41 Koren (ref_57) 2015; 4 Taverner (ref_29) 2018; 17 Maierean (ref_54) 2022; 2 Ridker (ref_14) 2007; 297 Pieterman (ref_18) 2014; 55 Oesterle (ref_9) 2017; 120 Muhlestein (ref_38) 2014; 63 Friedewald (ref_62) 1972; 18 Pradhan (ref_13) 2018; 138 Shapiro (ref_60) 2018; 122 Havel (ref_64) 1955; 34 Hansson (ref_1) 2017; 13 Nordestgaard (ref_49) 2014; 371 Kawakami (ref_24) 2006; 113 ref_27 Leung (ref_21) 2022; 362 Keser (ref_37) 2017; 60 Subirana (ref_47) 2020; 76 Robinson (ref_10) 2015; 372 Cao (ref_12) 2018; 8 Henry (ref_52) 2018; 20 Kelesidis (ref_41) 2015; 61 ref_36 ref_35 Berggren (ref_53) 2017; 28 Otvos (ref_39) 2018; 12 Malo (ref_34) 2021; 330 Kleber (ref_58) 2017; 106 Ballout (ref_25) 2020; 5 Ridker (ref_5) 2017; 377 Gencer (ref_4) 2020; 396 Lorenzo (ref_28) 2017; 40 Akinkuolie (ref_30) 2014; 3 Otvos (ref_26) 2015; 61 Joung (ref_23) 2020; 8 Joshi (ref_40) 2016; 119 Hiukka (ref_51) 2009; 58 Crosby (ref_50) 2014; 371 Jaafari (ref_19) 2021; 17 Padro (ref_55) 2021; 33 Toth (ref_56) 2018; 121 Ridker (ref_15) 2008; 118 Balogh (ref_22) 2019; 199 Nurmohamed (ref_3) 2021; 77 Hansson (ref_2) 2011; 12 Sliz (ref_44) 2018; 138 Balling (ref_48) 2020; 76 Gotto (ref_32) 2019; 5 Akinkuolie (ref_31) 2016; 5 Huo (ref_42) 2009; 49 Liu (ref_8) 2009; 119 Raal (ref_11) 2015; 385 Riggs (ref_46) 2022; 12 ref_7 Ricci (ref_17) 2018; 8 Kwakernaak (ref_59) 2014; 47 ref_6 |
| References_xml | – volume: 11 start-page: e023328 year: 2022 ident: ref_20 article-title: Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.121.023328 – volume: 18 start-page: 499 year: 1972 ident: ref_62 article-title: A Estimationofthe Concentrationof Low-Density LipoproteinCholesterolin Plasma, without Useof the PreparativeUltracentrifug publication-title: J. Chem. Inf. Model. – volume: 122 start-page: 1420 year: 2018 ident: ref_60 article-title: PCSK9 from basic science discoveries to clinical trials publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.118.311227 – volume: 138 start-page: 141 year: 2018 ident: ref_13 article-title: Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.034645 – volume: 5 start-page: 17 year: 2020 ident: ref_25 article-title: GlycA: A new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment publication-title: J. Lab. Precis. Med. doi: 10.21037/jlpm.2020.03.03 – volume: 30 start-page: 931 year: 2012 ident: ref_16 article-title: PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages publication-title: Int. J. Mol. Med. doi: 10.3892/ijmm.2012.1072 – volume: 8 start-page: 2267 year: 2018 ident: ref_17 article-title: PCSK9 induces a pro-inflammatory response in macrophages publication-title: Sci. Rep. doi: 10.1038/s41598-018-20425-x – volume: 63 start-page: A1389 year: 2014 ident: ref_38 article-title: GlycA and GlycB, Novel NMR Biomarkers of Inflammation, Strongly Predict Future Cardiovascular Events, But Not the Presence of Coronary Artery Disease (CAD), Among Patients Undergoing Coronary Angiography: The Intermountain Heart Collaborative Study publication-title: J. Am. Coll. Cardiol. doi: 10.1016/S0735-1097(14)61389-9 – volume: 61 start-page: 714 year: 2015 ident: ref_26 article-title: GlycA: A composite nuclear magnetic resonance biomarker of systemic inflammation publication-title: Clin. Chem. doi: 10.1373/clinchem.2014.232918 – volume: 12 start-page: 100373 year: 2022 ident: ref_46 article-title: GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis publication-title: Am. J. Prev. Cardiol. doi: 10.1016/j.ajpc.2022.100373 – volume: 12 start-page: 204 year: 2011 ident: ref_2 article-title: The immune system in atherosclerosis publication-title: Nat. Immunol. doi: 10.1038/ni.2001 – volume: 120 start-page: 229 year: 2017 ident: ref_9 article-title: Pleiotropic Effects of Statins on the Cardiovascular System publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.116.308537 – volume: 49 start-page: 976 year: 2009 ident: ref_42 article-title: Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2009.01.008 – volume: 40 start-page: 375 year: 2017 ident: ref_28 article-title: Novel protein glycan-derived markers of systemic inf lammation and c-reactive protein in relation to glycemia, insulin resistance, and insulin secretion publication-title: Diabetes Care doi: 10.2337/dc16-1569 – volume: 13 start-page: 368 year: 2017 ident: ref_1 article-title: The immunology of atherosclerosis publication-title: Nat. Rev. Nephrol. doi: 10.1038/nrneph.2017.51 – volume: 17 start-page: 3730 year: 2018 ident: ref_29 article-title: Characterization of 1H NMR Plasma Glycoproteins as a New Strategy to Identify Inflammatory Patterns in Rheumatoid Arthritis publication-title: J. Proteome Res. doi: 10.1021/acs.jproteome.8b00411 – volume: 28 start-page: 27 year: 2017 ident: ref_53 article-title: Apolipoprotein CIII is a new player in diabetes publication-title: Curr. Opin. Lipidol. doi: 10.1097/MOL.0000000000000372 – volume: 56 start-page: 737 year: 2015 ident: ref_63 article-title: Liposcale: A novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy publication-title: J. Lipid Res. doi: 10.1194/jlr.D050120 – volume: 330 start-page: 1 year: 2021 ident: ref_34 article-title: Serum glycoproteins A and B assessed by 1H-NMR in familial hypercholesterolemia publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2021.06.905 – volume: 199 start-page: 47 year: 2019 ident: ref_22 article-title: Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis publication-title: Clin. Immunol. doi: 10.1016/j.clim.2018.12.011 – volume: 385 start-page: 331 year: 2015 ident: ref_11 article-title: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(14)61399-4 – volume: 4 start-page: e002224 year: 2015 ident: ref_57 article-title: Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.115.002224 – volume: 33 start-page: 20 year: 2021 ident: ref_55 article-title: The role of triglycerides in the origin and progression of atherosclerosis publication-title: Clin. Investig. Arterioscler. – volume: 118 start-page: 343 year: 2017 ident: ref_43 article-title: Dietary intake of fat and fibre according to reference values relates to higher gut microbiota richness in overweight pregnant women publication-title: Br. J. Nutr. doi: 10.1017/S0007114517002100 – volume: 12 start-page: 348 year: 2018 ident: ref_39 article-title: Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial publication-title: J. Clin. Lipidol. doi: 10.1016/j.jacl.2018.01.002 – volume: 77 start-page: 1564 year: 2021 ident: ref_3 article-title: New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2020.11.079 – volume: 58 start-page: 2018 year: 2009 ident: ref_51 article-title: ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan publication-title: Diabetes doi: 10.2337/db09-0206 – volume: 18 start-page: 4038 year: 2019 ident: ref_33 article-title: Glycoprotein A and B Height-to-Width Ratios as Obesity-Independent Novel Biomarkers of Low-Grade Chronic Inflammation in Women with Polycystic Ovary Syndrome (PCOS) publication-title: J. Proteome Res. doi: 10.1021/acs.jproteome.9b00528 – volume: 61 start-page: 651 year: 2015 ident: ref_41 article-title: Changes in Inflammation and Immune Activation with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s publication-title: Clin. Infect. Dis. doi: 10.1093/cid/civ327 – volume: 119 start-page: 1242 year: 2016 ident: ref_40 article-title: GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.116.309637 – volume: 362 start-page: 29 year: 2022 ident: ref_21 article-title: Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2022.09.008 – volume: 8 start-page: 225 year: 2020 ident: ref_23 article-title: Association between IL-1beta and cardiovascular disease risk in patients with newly diagnosed, drug-naïve type 2 diabetes mellitus: A cross-sectional study publication-title: Ann. Transl. Med. doi: 10.21037/atm.2020.01.17 – volume: 371 start-page: 22 year: 2014 ident: ref_50 article-title: Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1307095 – volume: 8 start-page: e022348 year: 2018 ident: ref_12 article-title: Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: A systematic review and meta-analysis of randomised controlled trials publication-title: BMJ Open doi: 10.1136/bmjopen-2018-022348 – volume: 372 start-page: 1489 year: 2015 ident: ref_10 article-title: Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1501031 – volume: 5 start-page: e003822 year: 2016 ident: ref_31 article-title: Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.116.003822 – volume: 47 start-page: 679 year: 2014 ident: ref_59 article-title: Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins publication-title: Clin. Biochem. doi: 10.1016/j.clinbiochem.2014.03.008 – ident: ref_27 doi: 10.3390/jcm9020354 – ident: ref_36 doi: 10.3390/jcm9082472 – volume: 377 start-page: 1119 year: 2017 ident: ref_5 article-title: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1707914 – volume: 3 start-page: e001221 year: 2014 ident: ref_30 article-title: A novel protein glycan biomarker and future cardiovascular disease events publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.114.001221 – volume: 15 start-page: 219 year: 2017 ident: ref_45 article-title: GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk publication-title: J. Transl. Med. doi: 10.1186/s12967-017-1321-6 – volume: 113 start-page: 691 year: 2006 ident: ref_24 article-title: Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.105.591743 – volume: 76 start-page: 2725 year: 2020 ident: ref_48 article-title: VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2020.09.610 – volume: 76 start-page: 2712 year: 2020 ident: ref_47 article-title: Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2020.10.008 – volume: 118 start-page: 2243 year: 2008 ident: ref_15 article-title: C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds risk score for men publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.108.814251 – volume: 60 start-page: 2352 year: 2017 ident: ref_37 article-title: Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes publication-title: Diabetologia doi: 10.1007/s00125-017-4426-9 – volume: 138 start-page: 2499 year: 2018 ident: ref_44 article-title: Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared with Statin Treatment publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.034942 – ident: ref_35 doi: 10.3390/life11121407 – volume: 297 start-page: 611 year: 2007 ident: ref_14 article-title: Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women—The Reynolds Risk Score publication-title: J. Am. Med. Assoc. doi: 10.1001/jama.297.6.611 – volume: 106 start-page: 663 year: 2017 ident: ref_58 article-title: HDL cholesterol: Reappraisal of its clinical relevance publication-title: Clin. Res. Cardiol. doi: 10.1007/s00392-017-1106-1 – ident: ref_7 doi: 10.1007/s11883-014-0435-z – volume: 55 start-page: 2103 year: 2014 ident: ref_18 article-title: Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin publication-title: J. Lipid Res. doi: 10.1194/jlr.M051326 – volume: 2 start-page: oeac039 year: 2022 ident: ref_54 article-title: The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events publication-title: Eur. Heart J. Open doi: 10.1093/ehjopen/oeac039 – volume: 20 start-page: 1632 year: 2018 ident: ref_52 article-title: Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials publication-title: Diabetes Obes. Metab. doi: 10.1111/dom.13273 – volume: 119 start-page: 131 year: 2009 ident: ref_8 article-title: Evidence for statin pleiotropy in humans: Differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.108.813311 – volume: 34 start-page: 1345 year: 1955 ident: ref_64 article-title: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum publication-title: J. Clin. Investig. doi: 10.1172/JCI103182 – volume: 17 start-page: 1365 year: 2021 ident: ref_19 article-title: PCSK9 immunization using nanoliposomes: Preventive efficacy against hypercholesterolemia and atherosclerosis publication-title: Arch. Med. Sci. doi: 10.5114/aoms/133885 – volume: 5 start-page: 237 year: 2019 ident: ref_32 article-title: PCSK9 and inflammation: A review of experimental and clinical evidence publication-title: Eur. Heart J. Cardiovasc. Pharmacother. doi: 10.1093/ehjcvp/pvz022 – volume: 396 start-page: 1637 year: 2020 ident: ref_4 article-title: Efficacy and safety of lowering LDL cholesterol in older patients: A systematic review and meta-analysis of randomised controlled trials publication-title: Lancet doi: 10.1016/S0140-6736(20)32332-1 – volume: 371 start-page: 32 year: 2014 ident: ref_49 article-title: Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1308027 – volume: 121 start-page: 308 year: 2018 ident: ref_56 article-title: Effect of Evolocumab on Lipoprotein Particles publication-title: Am. J. Cardiol. doi: 10.1016/j.amjcard.2017.10.028 – volume: 41 start-page: 111 year: 2020 ident: ref_61 article-title: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehz455 – ident: ref_6 doi: 10.1161/CIRCRESAHA.120.315937 |
| SSID | ssj0023259 |
| Score | 2.4265833 |
| Snippet | Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9... HighlightsWhat are the main findings?PCSK9 inhibition significantly reduces 1H-NMR glycoprotein signals and does not affect hsCRP levels.Apolipoprotein C-III... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 2319 |
| SubjectTerms | Anti-Inflammatory Agents Apolipoprotein C-III Apolipoproteins Atherosclerosis Biomarkers C-Reactive Protein Cardiovascular Diseases - etiology Cholesterol Cholesterol, LDL Confounding (Statistics) Cytokines Glycoproteins Heart Disease Risk Factors High density lipoprotein Humans Hypertension Inflammation Inflammation - complications Inflammation - drug therapy Lipoproteins Low density lipoprotein Magnetic Resonance Spectroscopy - adverse effects Monoclonal antibodies NMR Nuclear magnetic resonance Observational studies PCSK9 Inhibitors Plasma Proprotein Convertase 9 - metabolism Proton Magnetic Resonance Spectroscopy Risk Factors Statins Triglycerides |
| SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELbGEBIviN8EBjIS8AJmiWM7yQNCVcVoQJ2mQaW9RbbjaIEu7doMkb-Jf5K7JI1WBrwl8smJ7M--O9_5PkJe5FwZvIHJwjA0TFjtWKKdYyLylTOJylWO952nh2oyE59O5MkO2eTP9wO4_qtrh3xSs9X87c_z5j0s-HfocYLLvl9-O1tjWTkwVZJXy3OGlFIYeu35Na6R66CmOEJ-KoYQA1gSLZNaAAqKKZmoLiv-Sofb-uqKEfpnLuUl5XRwm9zqrUo66mBwh-y46i650fFMNvfIr6Pxl88JTavT0pRIr0Mn-oejI2RoWC7aUg1lRccsTVPWZse5nI6qumRpVQBiztpIPB3ZjmniDe0ixSBkGhpM2OH0mH6cN3bo6agjAqfwCBsTnvSsqa4p5pTQxYrC6mm6l_FWNiw9Ltff75PZwYev4wnrWRqYhVGtmdOxyLUz0oLzVPi2UMIExsRCm9jJKOA6SCRPgtCJwDcStlMT4_VcFxgd-yYMH5DdalG5R4QK4cBeSoqY51ZIozTgS8nCBYU2Pk-sR15v5iKzfQlzZNKYZ-DK4Mxll2fOIy8H6WVXuuMfcnubac02-Ms4mMWgBySPPPJ8aIalh_EUXbnFRSuD7mMUxh552KFg-BAWwouVkB6JtvAxCGBZ7-2Wqjxty3uDxQ6j5j_-_289ITc5gBhPg7jYI7v16sI9BfuoNs9anP8G3BcTYw priority: 102 providerName: Scholars Portal |
| Title | PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36768645 https://www.proquest.com/docview/2774911527 https://www.proquest.com/docview/2775625738 https://pubmed.ncbi.nlm.nih.gov/PMC9917120 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: HH5 dateStart: 20000101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: KQ8 dateStart: 20070101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: KQ8 dateStart: 20000101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVEBS databaseName: Academic Search Ultimate | Ebsco customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: ABDBF dateStart: 20081201 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: DIK dateStart: 20000101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: RPM dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: 7X7 dateStart: 20000301 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: BENPR dateStart: 20000301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Technology Collection customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: 8FG dateStart: 20000301 isFulltext: true titleUrlDefault: https://search.proquest.com/technologycollection1 providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1422-0067 dateEnd: 20250831 omitProxy: true ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: M48 dateStart: 20070101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYJiReEN8rG5WR4AmsxY7tJE-oVOtaUKuqMKlvlZ04WmBLuiVD6t_EP8ldkoYVBC9RopySKPdt392PkDeJ0BY7MJnv-5bJ2DgWGeeYDDztbKQTnWC_83Smx-fy01It2wW3si2r3NrE2lAnRYxr5CcC4hRQTCWCD-trhqhRuLvaQmjskQMuQJKwU3x01iVcvqjB0jj4IKZVpJvCdx_S_JPs21WJo-ggvIl2XdJfceaf5ZJ3_M_oEXnYBo500HD6Mbnn8ifkfgMluXlKfs6HXz5HdJJfZDZDBB06Nj8cHSAIw7qopzFkOR2yyWTC6gI4l9BBXmVskqcgFFf1ZjsdxA2YxHvabAYDkd1QPmaz6YKeXW7i7knzBuubwinYHlzMKampKJaN0OKGgoJsmovhTsErXWTl92fkfHT6dThmLRADiyUXFXMmlIlxVsWQH6VenGppubWhNDZ0KuDC8EiJiPtOcs8qsJg2xA5cx60JPev7z8l-XuTukFApHYREURqKJJbKagMipFXqeGqsJ6K4R95tebGK2ynlCJZxuYJsBTm3usu5HnnbUa-b6Rz_oDvesnXV6mi5-i1RPfK6uw3ahVsmJnfFbU2DGWLghz3yopGC7kU46y7UUvVIsCMfHQFO7t69k2cX9QRvCMrhr3kv__9ZR-QBgtvjgo-Qx2S_url1ryAEqmyf7AXLoF9Le58cfDydzRd9dEoKjlMZ_gLmuA1x |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb5RAEN40NUZfjL9Fq66JfdJNYVkWeDDmclrB612a2ib3hruwpGgLZ49q-JtM_BudgYP2NPrWN8hOgDDfzM7szs5HyMuMS40nMJnrupqJVBkWKmOY8G1pdCgzmeF55-lMRkfi49ybb5Bf_VkYLKvsfWLrqLMqxTXyHQ5xChimx_23i28MWaNwd7Wn0OhgMTHND0jZlm_id6Dfbc533x-OI7ZiFWCpcHjNjApEpoz2Ugj2czvNpdCO1oFQOjCe73DlhB4PHdcIx9YemL8O8DipcbQKbI0LoODyrwnXFtir359fJHgub8nZHJjzmPRC2RXau25o7xRfTpfY-g7CqXB9Cvwrrv2zPPPSfLd7m9xaBap01CHrDtkw5V1yvaOubO6Rn_vjT5OQxuVxoQtk7KGR-m7oCEkfFlXb_aEo6ZjFcczagjuT0VFZFywucwDhabu5T0dpR17xmnabzyCkG-pEbDY9oB9OmnR40n7HLU7hEnwdLh4tqaoplqnQ6oyCQTbdzXitwJYeFMuv98nRlajoAdksq9I8IlQIAyFYmAc8S4WnpQLISi83Tq60zcPUIq96XSTpqis6knOcJJAdoeaSy5qzyPYgvei6gfxDbqtXa7LyCcvkAsEWeTEMgzXjFo0qTXXeymBG6ruBRR52KBhehL31Aik8i_hr-BgEsFP4-khZHLcdwyEJgL9mP_7_Zz0nN6LD6V6yF88mT8hNDoDGxSYutshmfXZunkL4VetnLeYp-XzVRvYbTRpGzg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemIRAviP9kG2Ak9gTWYsdxkgeEqo7SUFZVg0l9y-zE0QJbUtYM1M_EN-DTcZek3QqCt70l8imJcr8739nn-xHyMhPK4AlM5nmeYTLVlkXaWiYDV1kTqUxleN75YKyGR_LD1J9ukF_LszBYVrn0iY2jzqoU18j3BMQpYJg-pOp5VxYx2R-8nX1jyCCFO61LOo0WIiO7-AHp2_xNvA-63hVi8O5zf8g6hgGWSi5qZnUoM22Nn0Lgn7tprqThxoRSm9D6AReaR76IuGcld40PrsCEeLTUcqND1-BiKLj_G4EnPSwnC6aXyZ4nGqI2DvMfU36k2qJ7z4vcveLL2Rzb4EFoFa1Ph3_FuH-Wal6Z-wZ3yZ0uaKW9FmX3yIYt75ObLY3l4gH5Oel_GkU0Lk8KUyB7Dx3q75b2kABiVjWdIIqS9lkcx6wpvrMZ7ZV1weIyB0CeNRv9tJe2RBavabsRDUJmQfmQjQ8O6fvTRbp60qTlGadwCX4PF5LmVNcUS1ZodU7BOBftTX-t2JYeFvOvD8nRtajoEdksq9I-IVRKC-FYlIciS6VvlAb4Kj-3PNfGFVHqkFdLXSRp1yEdiTpOE8iUUHPJVc05ZHclPWs7g_xDbmep1qTzD_PkEs0OebEaBsvG7Rpd2uqikcHsNPBChzxuUbB6EfbZC5X0HRKs4WMlgF3D10fK4qTpHg4JAfw1d-v_n_Wc3ALzSj7G49E2uS0Az7juJOQO2azPL-xTiMRq86yBPCXH121jvwFPUUsJ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PCSK9+Inhibitors+Have+Apolipoprotein+C-III-Related+Anti-Inflammatory+Activity%2C+Assessed+by+1H-NMR+Glycoprotein+Profile+in+Subjects+at+High+or+very+High+Cardiovascular+Risk&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Rehues%2C+Pere&rft.au=Girona%2C+Josefa&rft.au=Guardiola%2C+Montse&rft.au=Plana%2C+N%C3%BAria&rft.date=2023-01-24&rft.pub=MDPI+AG&rft.issn=1661-6596&rft.eissn=1422-0067&rft.volume=24&rft.issue=3&rft.spage=2319&rft_id=info:doi/10.3390%2Fijms24032319&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon |